Navigation Links
ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
Date:10/29/2008

upply or distribution interruptions, including but not

limited to our ability to acquire adequate supplies of Vancocin and

Cinryze to meet demand for the product;

-- changes in prescribing or procedural practices of infectious disease,

gastroenterology and internal medicine doctors, including off-label

prescribing of other products;

-- the timing of regulatory submissions and approvals;

-- actions by the FDA, EMEA and the Internal Revenue Service or other

government regulatory agencies;

-- decreases in the rate of infections for which Vancocin is prescribed;

-- decrease in the sensitivity of the relevant bacteria to Vancocin;

-- our ability to successfully integrate the business of Lev

Pharmaceuticals, Inc.;

-- the timing and results of anticipated events in the Company's CMV and

NTCD programs; and

-- the timing and nature of potential business development activities

related to the Company's efforts to expand its current portfolio

through in-licensing or other means of acquiring products in clinical

development or marketed products.

There can be no assurance that FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of the company's product candidates, or that the company will be successful in gaining regulatory approval of any of its product candidates.

These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission during 2008, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-loo
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
2. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
4. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
5. ViroPharma Provides Update on Vancocin(R)
6. ViroPharma Augments Senior Management
7. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
8. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
9. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
10. ViroPharma to Present at the UBS Global Life Sciences Conference
11. ViroPharma to Present at the Maxim Group First Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... As interest in the value of spiritual support ... Rev. Eric J. Hall , president and CEO of ... be the keynote speaker on January 27 at an international ... , The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... 11 The Guidebook of Sexual Medicine,was ... as the main unit for,treatment of sexual ... the thorough evaluation of biological factors (e.g., ... psychosocial factors (e.g.,presence of depression, relational conflicts, ...
... Welcome to Consumer,Reports Health News for health ... issues pertaining to the efficacy and safety,of ... health, diet and nutrition, food safety, and ... the effectiveness and affordability of,prescription drugs, and ...
... 11, 2008) The World Bank and Conservation International ... new funds, provided by the Global Environment Facility (GEF), ... threatened areas, including island ecosystems and temperate forests. , ... of all terrestrial plants and animals, as well as ...
... drugs reduce risk of major vascular events , FRIDAY, ... be considered for treatment with cholesterol-lowering statins. , That,s the ... 12 issue of The Lancet . , The British ... major vascular events in a wide range of people with ...
... offered free by LifeSpan Nutrition, SAN DIMAS, Calif., ... Family Guide To Vitamin D", which reveals,the new unfolding ... health and the health of your loved ones., ... says,achieving adequate levels of vitamin D will do more ...
... MONTREAL, Jan. 11 /PRNewswire-FirstCall/ - DRAXIS Health Inc, (TSX:,DAX) (NASDAQ: ... (TSX) to make,a Normal Course Issuer Bid (NCIB), subject to ... of the TSX., The maximum number of common shares ... such number of common shares which,represents 10% of the common ...
Cached Medicine News:Health News:A New Book on Sexual Medicine Calls Attention to 'The Couple' and Presents State-of-the Art Treatments for Sexual Dysfunction 2Health News:Consumer Reports Health News 2Health News:Consumer Reports Health News 3Health News:Consumer Reports Health News 4Health News:Global Environment partners provide additional $20 million to protect endangered habitats 2Health News:Statin Therapy Helps Diabetic Patients 2Health News:Join the Vitamin D Revolution: How to Get 30 Minutes of Daily Sunshine for Optimal Health 2Health News:DRAXIS Announces Application for Normal Course Issuer Bid 2Health News:DRAXIS Announces Application for Normal Course Issuer Bid 3Health News:DRAXIS Announces Application for Normal Course Issuer Bid 4
(Date:1/23/2015)... Ala. , Jan. 23, 2015 Gem Pharmaceuticals ... patients have been enrolled into the Company,s Phase 2 ... and safety of Gem,s lead compound, GPX-150 (an investigational ... advanced or metastatic disease. Logo - ...
(Date:1/23/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... and sale of patented biopharmaceutical medicine, modernized traditional Chinese ... today announced the business and development progress at its ... Following the September 2014 JCM application (No. 51268) for ...
(Date:1/22/2015)... 2015  BiOptix is pleased to announce the appointment of ... Chemistry and Biochemistry. Scott joins the company after previous scientific ... throughout the course of his nearly 20 year career ... a nationally recognized thought leader in the biosensor field ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Shire plc (LSE: SHP,Nasdaq: SHPGY), the global ... scientific meeting findings from analyses of pivotal ... compound is an,investigational once-daily medication, which is ... of Attention Deficit Hyperactivity Disorder,(ADHD). The data ...
... and 2 Data Expected at ASCO in June ... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a ... has completed patient enrollment in,its Phase 2 clinical ... of metastatic colorectal cancer (CRC). Early,data from this ...
Cached Medicine Technology:Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 2Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 3Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 4Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 5Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 6Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 2Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 3Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer 4
...
...
...
Rhoton Curettes, titanium, length 191 mm, straight....
Medicine Products: